Lantheus (NASDAQ:LNTH) Releases FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 6.600-6.700 for the period, compared to the consensus earnings per share estimate of 7.050. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Analyst Ratings Changes

LNTH has been the topic of several recent analyst reports. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Truist Financial reduced their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $132.67.

Lantheus Trading Down 1.9%

Shares of LNTH stock traded down $1.56 on Monday, reaching $80.19. 928,270 shares of the stock were exchanged, compared to its average volume of 968,906. Lantheus has a twelve month low of $75.00 and a twelve month high of $126.89. The company has a market capitalization of $5.49 billion, a price-to-earnings ratio of 13.35 and a beta of 0.23. The business's 50 day moving average price is $99.57 and its 200 day moving average price is $94.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company's revenue was up .8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.69 earnings per share. Equities research analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock valued at $6,016,046. 1.50% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.